What is a normal nuchal translucency (NT) measurement?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Normal Nuchal Translucency Measurement

A normal nuchal translucency (NT) measurement is defined as less than 3 mm or below the 99th percentile for crown-rump length when measured between 11+0 and 14+0 weeks of gestation. 1

Measurement Parameters and Timing

  • NT measurement must be performed between 11+0 and 14+0 weeks of gestation, as the measurement is crown-rump length dependent and loses predictive value outside this window. 2

  • The NT measurement increases physiologically with crown-rump length, so gestational age must be considered when determining if a measurement is abnormal—a single fixed cutoff cannot be applied across all gestational ages within the screening window. 1, 2

  • Transabdominal ultrasound can successfully obtain NT measurements in approximately 95% of patients, with transvaginal ultrasound reserved for cases where optimal views cannot be obtained transabdominally. 1

Definition of Abnormal Values

  • An increased (abnormal) NT is defined as a measurement ≥3 mm or above the 99th percentile for the crown-rump length. 1

  • Some research suggests that NT measurements between 2.5-2.9 mm may represent a "gray zone" with intermediate risk, showing a 2.5-fold increased risk of aneuploidy compared to NT <2.5 mm, though this remains below the standard clinical threshold for abnormal. 3

  • Historical literature has variably used cutoffs of ≥2.5 mm or ≥3 mm to define abnormal measurements, though the current standard clinical threshold is ≥3 mm. 4, 5

Clinical Context and Limitations

  • A normal NT measurement (below 3 mm) is reassuring but should not be used in isolation to determine aneuploidy risk, as NT assessment alone detects only approximately 70% of trisomy 21 fetuses. 1, 2

  • When combined with maternal serum markers (pregnancy-associated plasma protein A and free beta-hCG), first trimester combined screening detects approximately 90% of affected pregnancies at a 5% false-positive rate. 1

  • Most cases of congenital heart disease have normal NT thickness—less than 25% of major heart defects are detected using the 99th percentile cutoff in euploid fetuses, confirming that normal NT does not exclude cardiac anomalies. 1

Important Caveats

  • Standardized measurement techniques are essential for accuracy, as established by organizations like the Fetal Medicine Foundation and Nuchal Translucency Quality Review Program—the small size of NT (typically <3 mm) approximates the threshold of normal inter-examiner and intra-examiner variability. 2, 4

  • Normal NT measurements do not replace the need for second trimester anatomic survey, as only 50% of major fetal anomalies can be detected prior to 14 weeks with a 3-4% false-positive rate at this early gestational age. 1

  • In high-risk populations (such as women over 35 years), a normal NT measurement should not discourage invasive testing if otherwise indicated, as the data are unclear whether normal NT decreases the likelihood of chromosomal abnormality sufficiently in these patients. 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Nuchal Translucency Scan Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Diagnosis and management of fetal nuchal translucency.

Seminars in roentgenology, 1998

Research

Nuchal translucency: an ultrasound marker for fetal chromosomal abnormalities.

Sao Paulo medical journal = Revista paulista de medicina, 2001

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.